close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Polyrizon Ltd. - Ordinary Shares (NQ:PLRZ)

1.055 -0.015 (-1.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Polyrizon Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
Polyrizon Ltd. Announces $17.0 Million Private Placement
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
From Polyrizon Ltd.
Via GlobeNewswire
Top movers in Tuesday's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
From Clearmind Medicine Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Is Development-Stage Biotech Company Polyrizon Stock Surging Today?
Polyrizon shares rise after disclosing the publication of a national phase patent application for nasal protection and drug delivery technologies. 
Via Benzinga
Topics Intellectual Property
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Crude Oil Gains Over 1%, General Mills Shares Fall
 
Via Benzinga
What's Going On With Polyrizon Shares Wednesday?
Polyrizon shares are moving higher after the company announced it secured a manufacturing agreement with Eurofins CDMO Amatsiaquitaine. 
Via Benzinga
Dow Surges 150 Points, US Current Account Deficit Widens In Q3
 
Via Benzinga
Topics Stocks
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
From Polyrizon Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today